Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript February 5, 2026 Illumina, Inc. beats earnings expectations.

Total company revenue is projected at “$4.5 billion to $4.6 billion, representing reported growth of 4% to 6%,” with operating margins expected at 23.3% to 23.5% in 2026. EPS guidance is “$5.05 to ...

US genomics specialist Illumina (Nasdaq: ILMN) has completed its acquisition of proteomics company SomaLogic, adding large-scale protein analysis to its multiomics portfolio and strengthening its push ...

The latest announcement is out from Illumina ( (ILMN) ).

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's ...

Illumina, Inc. today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics ...

Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...

Agilus Diagnostics unveils Illumina NovaSeq X to bolster India’s capacity for NGS at scale: Our Bureau, Bengaluru Wednesday, January 28, 2026, 17:15 Hrs [IST] Agilus Diagnostics ...

Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related prod ...

The Illumina NovaSeq X adds to Agilus Diagnostics’ molecular testing portfolio through high-throughput sequencing and ...

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

The Global Consumer Genomics Market is primed for growth due to decreasing sequencing costs and rising health awareness, expanding from USD 2.72 Billion in 2025 to USD 8.02 Billion by 2031.